In premenopausal hormone receptor-positive breast cancer after chemotherapy, adding goserelin improved 5-year disease-free survival versus tamoxifen alone.
In plain wordsIn premenopausal breast cancer after chemotherapy, adding goserelin improved disease-free survival compared with tamoxifen alone.
- Peptide
- Goserelin
- Outcome
- Increase5-year disease-free survival
- Study
n = 1,282
- Comparator
- Tamoxifen alone
- Outcome group
- Tumor growth · Cancer
- Studied dose
- monthly administration · 2 yearsAs given in this study (human).
Measurements
- Disease-free survival
- 91.1%
- goserelin plus tamoxifen at 5 years
- Disease-free survival
- 87.5%
- tamoxifen at 5 years
- Hazard ratio
- 0.69
- 95% CI 0.48-0.97; P = .033
Source sentences
The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033).
2 context sentences(design, population, supporting numbers)
We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy.
If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years of TAM alone (TAM-only) group or 5 years of TAM with OFS for 2 years that involved monthly goserelin administration (TAM + OFS) group.